/

CERS

Cerus CorporationAfter hours

2.260.00 0.00%USD

NasdaqGM · as of Oct 13, 16:00 ET · 15m delayAfter hours 2.26 0.00%

Open

2.28

Prev close

2.26

Day range

2.242.32

52-week range

1.383.47

Volume

2.29M1.07×

Mkt cap

455.45M

P/E ttm

—

Fwd P/E

-452.00

EPS ttm

-0.0300

Div yield

0.00%

Earnings

Jul 30, 2026

From 52w high

−34.87%

Price Chart

Yahoo Finance · delayed

CERSOct 13, 2026O 2.28H 2.32L 2.23C 2.260.00 (0.00%)Vol 2.29M

SMA 502.55
SMA 2002.44

1Y change +41.25% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

CERS Cerus Corporation · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −3.42%
1 month: −9.24%
3 months: −26.38%
6 months: +12.44%
Year to date: +9.71%
1 year: +44.87%

Valuation & ownership

Market cap: 455.45M
Enterprise value: 476.67M
P/E (ttm): —
Forward P/E: -452.00
PEG ratio: —
Price / book: 6.49
Price / sales (ttm): 2.06
EV / EBITDA: 7222.31
EPS (ttm): -0.0300
EPS (forward): -0.005000
Beta (5y monthly): 1.83
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 201.52M
Float: 195.35M
Short % of float: 8.98%
Short ratio (days): 10.54
Held by insiders: 3.61%
Held by institutions: 73.47%
Avg volume (3m): 2.13M
50-day average: 2.55
200-day average: 2.44
52-week change: +44.87%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 34.9
vs 50-day SMA: −11.29%
vs 200-day SMA: −7.34%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 4.48%
Realised vol (20d, ann.): 43.6%
From 52-week high: −34.87%
From 52-week low: +63.77%

ANR

Analyst Consensus

4 analysts

Consensus

—

Mean target

5.13

+126.77% implied

Low 4.00Median 5.00High 6.50

Recommendation trend

Now4 / 0 / 0
1m ago3 / 0 / 0

Buy / hold / sell counts

DES

About Cerus Corporation

Yahoo Finance profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.

Sector: Healthcare
Industry: Medical Devices
Employees: 261
Headquarters: Concord, CA, United States
Website: cerus.com
Officers: Mr. William M. Greenman

SEAS

Seasonality · CERS

2007–2026 · monthly returns

Strongest month Jul +7.41%Weakest month Oct −7.76%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	13.1	9.9	-28.9	11.5	49.8	-3.9	-26.4	22.8	-9.8	-5.0			+9.7%
2025	21.4	-11.8	-15.8	-5.0	-3.8	11.0	-9.2	2.3	21.4	-7.5	19.7	17.0	+33.8%
2024	-16.2	20.4	-13.3	-11.6	7.2	-1.7	28.4	0.0	-23.0	-9.8	17.8	-16.8	−28.7%
2023	-14.0	-8.9	3.8	-22.2	-7.4	15.0	24.8	-38.4	-14.3	-13.6	15.0	34.2	−40.8%
2022	-21.3	9.5	-6.5	-15.8	7.1	6.9	2.1	-23.9	-12.4	1.7	9.3	-8.7	−46.4%
2021	-4.8	-6.8	-2.1	1.5	-5.1	2.1	-14.7	28.0	-5.6	8.4	4.4	-1.2	−1.6%
2020	-5.0	28.2	-9.5	32.3	1.1	6.1	8.0	-10.7	-1.7	-16.1	26.7	4.1	+64.0%
2019	17.6	9.2	-4.3	-1.6	-23.5	19.8	4.1	-8.2	-3.9	-15.7	-0.2	-2.8	−16.8%
2018	31.1	-3.4	28.0	-5.1	26.7	1.2	11.1	5.0	-7.3	-7.1	-21.6	-3.4	+50.0%
2017	-2.1	-1.6	6.2	-2.2	-47.4	9.6	-10.0	4.0	16.2	5.1	37.6	-14.4	−22.3%
2016	-14.1	-9.8	21.0	5.6	-11.2	12.2	18.4	-14.3	-1.9	-22.4	8.3	-16.7	−31.2%
2015	-14.4	-10.5	-12.8	6.5	12.2	4.2	4.6	-8.7	-8.5	5.1	18.9	11.5	+1.3%
2014	-4.3	4.7	-25.7	-9.8	-3.2	-1.0	-15.2	6.8	6.6	3.7	8.9	37.7	−3.3%
2013	0.3	3.8	34.3	20.4	-3.4	-14.0	26.7	-6.6	28.5	-6.1	6.0	-3.6	+104.1%
2012	1.8	31.9	6.9	-2.0	-14.2	-1.8	-9.0	5.6	6.6	-8.8	4.2	-2.2	+12.9%
2011	34.1	4.2	-15.4	1.7	1.4	0.0	-7.7	-26.0	3.4	25.9	12.0	-6.4	+13.8%
2010	-7.5	33.2	13.9	16.1	-2.5	0.0	-1.9	-7.4	33.8	-14.3	-26.7	2.1	+23.6%
2009	34.3	-21.3	-8.1	72.1	6.0	-16.9	62.1	26.3	3.8	-23.3	8.3	9.3	+184.3%
2008	-3.2	-0.8	-7.7	8.0	-20.7	-17.2	24.0	-12.0	-7.4	-55.7	-42.6	-33.3	−89.2%
2007	-1.0	-7.9	26.4	10.2	-16.4	8.7	-5.9	8.8	26.2	3.1	-14.2	-15.7	+11.1%

INSD

Insider Activity · CERS

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

1.06M shares

Sells, 6 months

302.7K shares

Net shares

+755.4K

Net change in insider shares

+11.60%

Date	Insider	Transaction	Shares	Value
Aug 16, 2026	Jensen Chrystal MenardOfficer	Sale at price 2.98 per share.	30K	$89.53K
Jul 15, 2026	Jayaraman Vivek K.Chief Executive Officer	Sale at price 3.16 per share.	16.7K	$52.66K
Jun 30, 2026	Jayaraman Vivek K.Chief Operating Officer	Stock Award(Grant) at price 0.00 per share.	634.5K	—
Jun 29, 2026	Green Kevin DennisChief Financial Officer	Sale at price 2.94 per share.	33.7K	$99.11K
Jun 29, 2026	Jensen Chrystal MenardOfficer	Sale at price 2.94 per share.	24.3K	$71.60K
Jun 29, 2026	Jayaraman Vivek K.Chief Operating Officer	Sale at price 2.94 per share.	42.4K	$124.66K
Jun 29, 2026	Greenman William MarinerChief Executive Officer	Sale at price 2.94 per share.	101.9K	$299.94K
Jun 29, 2026	Green Kevin DennisChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	63.6K	—
Jun 8, 2026	Bjerkholt Eric HDirector	Sale at price 2.60 per share.	20.5K	$53.18K
Jun 1, 2026	Bjerkholt Eric HDirector	Stock Award(Grant) at price 0.00 per share.	60K	—
Jun 1, 2026	Lucena AnnDirector	Stock Award(Grant) at price 0.00 per share.	60K	—
Jun 1, 2026	Shan HuaDirector	Stock Award(Grant) at price 0.00 per share.	60K	—
Jun 1, 2026	Gregory Dean A.Director	Stock Award(Grant) at price 0.00 per share.	60K	—
Jun 1, 2026	Witney Franklin R. Ph.D.Director	Stock Award(Grant) at price 0.00 per share.	60K	—
Jun 1, 2026	Nachtsheim Jami Dover KDirector	Stock Award(Grant) at price 0.00 per share.	60K	—
May 28, 2026	Jayaraman Vivek K.Chief Operating Officer	Sale at price 3.00 per share.	16.7K	$50.00K
Apr 30, 2026	Jayaraman Vivek K.Chief Operating Officer	Sale at price 3.00 per share.	16.7K	$50.00K
Mar 31, 2026	Green Kevin DennisChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	200K	—
Mar 31, 2026	Jensen Chrystal MenardOfficer	Stock Award(Grant) at price 0.00 per share.	200K	—
Mar 11, 2026	Green Kevin DennisChief Financial Officer	Sale at price 1.66 per share.	127.5K	$211.37K

13F

Investors Holding CERS

latest 13F filings of 29 followed managers

Investors holding CERS
Investor	Value	Of portfolio	Shares	Change	Quarter
ARK Investment Management · Cathie Wood	$52.4M	0.34%	17.93M	−6.4%	Q2 2026
Renaissance Technologies	$2.0M	0.00%	671.70K	+16%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

CERS

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

CERS

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Cerus Corporation

Seasonality · CERS

Insider Activity · CERS

Congress Trades · CERS

Investors Holding CERS

Investors Holding CERS

Congress Trades · CERS

Insider Activity · CERS

Seasonality · CERS

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Cerus Corporation

Financial Snapshot

Earnings & Dividends

News